Several countries have authorised or begun using a booster vaccine dose against COVID-19. Policy makers urgently need evidence of the effectiveness of additional vaccine doses and its clinical ...spectrum for individuals with complete primary immunisation schedules, particularly in countries where the primary schedule used inactivated SARS-CoV-2 vaccines.
Using individual-level data, we evaluated a prospective, observational, national-level cohort of individuals (aged ≥16 years) affiliated with the Fondo Nacional de Salud insurance programme in Chile, to assess the effectiveness of CoronaVac (Sinovac Biotech), AZD1222 (Oxford-AstraZeneca), or BNT162b2 (Pfizer-BioNTech) vaccine boosters in individuals who had completed a primary immunisation schedule with CoronaVac, compared with unvaccinated individuals. Individuals administered vaccines from Feb 2, 2021, to the prespecified study end date of Nov 10, 2021, were evaluated; we excluded individuals with a probable or confirmed SARS-CoV-2 infection (RT-PCR or antigen test) on or before Feb 2, 2021, and individuals who had received at least one dose of any COVID-19 vaccine before Feb 2, 2021. We estimated the vaccine effectiveness of booster doses against laboratory-confirmed symptomatic COVID-19 (symptomatic COVID-19) cases and COVID-19 outcomes (hospitalisation, admission to the intensive care unit ICU, and death We used inverse probability-weighted and stratified survival regression models to estimate hazard ratios, accounting for time-varying vaccination status and adjusting for relevant demographic, socioeconomic, and clinical confounders. We estimated the change in hazard from unvaccinated status to vaccinated status associated with the primary immunisation series and a booster vaccine.
11 174 257 individuals were eligible for this study, among whom 4 127 546 completed a primary immunisation schedule (two doses) with CoronaVac and received a booster dose during the study period. 1 921 340 (46·5%) participants received an AZD1222 booster, 2 019 260 (48·9%) received a BNT162b2 booster, and 186 946 (4·5%) received a homologous booster with CoronaVac. We calculated an adjusted vaccine effectiveness (weighted stratified Cox model) in preventing symptomatic COVID-19 of 78·8% (95% CI 76·8–80·6) for a three-dose schedule with CoronaVac, 96·5% (96·2–96·7) for a BNT162b2 booster, and 93·2% (92·9–93·6) for an AZD1222 booster. The adjusted vaccine effectiveness against COVID-19-related hospitalisation, ICU admission, and death was 86·3% (83·7–88·5), 92·2% (88·7–94·6), and 86·7% (80·5–91·0) for a homologous CoronaVac booster, 96·1% (95·3–96·9), 96·2% (94·6–97·3), and 96·8% (93·9–98·3) for a BNT162b2 booster, and 97·7% (97·3–98·0), 98·9% (98·5–99·2), and 98·1% (97·3–98·6) for an AZD1222 booster.
Our results suggest that a homologous or heterologous booster dose for individuals with a complete primary vaccination schedule with CoronaVac provides a high level of protection against COVID-19, including severe disease and death. Heterologous boosters showed higher vaccine effectiveness than a homologous booster for all outcomes, providing additional support for a mix-and-match approach.
Agencia Nacional de Investigación y Desarrollo through the Fondo Nacional de Desarrollo Científico y Tecnológico, Millennium Science Initiative Program, and Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias.
Background and Aims
During the COVID‐19 pandemic, mental health became a relevant factor in people's performance within organizations. The aim of this study was to analyze the effects of an ...organizational intervention program on the psychosocial factors of demands, resources, and the consequences of psychosocial risks in a technology services company during the COVID‐19 pandemic.
Methods
A quasiexperimental study was carried out with 105 employees who took part in an 8‐week intervention program divided into two large stages. Pre‐ and postmeasurements were collected using the UNIPSICO Questionnaire, considering its factors of demands, resources, and consequences of psychosocial risks. The Spanish Burnout Inventory (SBI) was also included.
Results
The results showed significant improvements in the perception of the following psychosocial demand factors: Role conflict (p < 0.001), Role ambiguity, workload, interpersonal conflicts (p < 0.05). In the resource factors: autonomy, work social support, feedback (p < 0.001) Resources at work, transformational leadership, and self‐efficacy (p < 0.05). In addition, all the consequences of psychosocial risks have improvements: Indolence, emotional exhaustion, and job satisfaction (p < 0.001), Burnout syndrome, enthusiasm toward the job, and psychosomatic problems (p < 0.05), except the Guilt dimension of the SBI.
Conclusion
We can conclude that the program was effective and that the study limitations should be improved in future studies.
Objetivo. La presente investigación tiene como objetivo identificar los aspectos individuales que, en conjunto con aquellos propios del trabajo pedagógico y el contexto en el cual este se desarrolla, ...contribuyen al fortalecimiento de la resiliencia docente en profesorado. Metodología. En cuanto a la metodología, se trata de un estudio cualitativo de casos múltiples que incluye a once docentes noveles de enseñanza media que laboran en colegios públicos. Se utilizaron entrevistas y mensajes de audio vía plataforma WhatsApp, que fueron sometidos a análisis de contenido. Resultados. Los resultados muestran que la principal dificultad que enfrentó el personal docente corresponde al bajo rendimiento del estudiantado, situación que enfrentan a partir de la renovación de sus prácticas de enseñanza desde lo didáctico y evaluativo. El personal docente estudiado tiene en común una visión positiva acerca de las capacidades de sus estudiantes, la autonomía profesional, un alto compromiso con el aprendizaje del estudiantado, una visión común en torno al sentido de su labor y su contribución social. Estos aspectos compartidos contribuyen a un vínculo positivo con los pares y al desarrollo de innovaciones conjuntas en el marco del trabajo colaborativo. Conclusiones. Las conclusiones del estudio establecen el compromiso moral con la enseñanza del personal docente y la contribución de la innovación pedagógica en el incremento de su sentido de logro, así como la necesidad de generar condiciones institucionales que permitan fortalecer la resiliencia del profesorado principiante, brindando condiciones materiales y generando condiciones para el trabajo colaborativo docente que permita consolidar comunidades de aprendizaje profesional.
RESUMEN
Objetivo.
Caracterizar y describir las notificaciones de sospechas de reacciones adversas de un grupo de medicamentos que se utilizaron en Colombia, Costa Rica, Cuba, Chile, El Salvador, ...México y Perú para tratar o prevenir la enfermedad por el coronavirus (COVID-19, por su sigla en inglés) entre el 1 de marzo y el 31 de agosto del 2020.
Métodos.
Se elaboró una lista de los 13 medicamentos utilizados para tratar o prevenir la COVID-19, según fuentes oficiales y no oficiales. Desde las bases de datos de los programas nacionales de farmacovigilancia de los países participantes, se recopilaron las notificaciones de sospechas de reacciones adversas a estos medicamentos recibidas en el período comprendido entre el 1 de marzo y 31 de agosto de año 2020.
Resultados.
Se recibieron 3 490 notificaciones de sospechas de reacciones adversas desde los programas de farmacovigilancia de Perú (n = 3 037), Cuba (n = 270), Colombia (n = 108), Chile (n = 72) y El Salvador (n = 3). Los medicamentos con mayor número de notificaciones de reacciones adversas fueron la azitromicina, la ivermectina y la hidroxicloroquina. La diarrea fue el evento más frecuente (15,0%). Del total de las sospechas de reacciones adversas, 11,9% fueron notificadas como graves. La más frecuente fue la prolongación del intervalo QT posterior al uso de hidroxicloroquina. De estas sospechas de reacciones adversas graves, 54,5% ocurrieron en personas mayores de 65 años.
Conclusión.
Si bien no es posible establecer una relación causal a partir de la evaluación de informes espontáneos, el presente estudio confirma la presencia de reacciones adversas, algunas graves, con medicamentos que se utilizaron para tratar o prevenir la COVID-19.
Policymakers urgently need evidence to adequately balance the costs and benefits of mass vaccination against COVID-19 across all age groups, including children and adolescents. In this study, we aim ...to assess the effectiveness of CoronaVac's primary series among children and adolescents in Chile.
We used a large prospective national cohort of about two million children and adolescents 6–16 years to estimate the effectiveness of an inactivated SARS-CoV-2 vaccine (CoronaVac) in preventing laboratory-confirmed symptomatic SARS-CoV-2 infection (COVID-19), hospitalisation, and admission to an intensive care unit (ICU) associated with COVID-19. We compared the risk of individuals treated with a complete primary immunization schedule (two doses, 28 days apart) with the risk of unvaccinated individuals during the follow-up period. The study was conducted in Chile from June 27, 2021, to January 12, 2022, when the SARS-CoV-2 Delta variant was predominant but other variants of concern were co-circulating, including Omicron. We used inverse probability-weighted survival regression models to estimate hazard ratios of complete immunization over the unvaccinated status, accounting for time-varying vaccination exposure and adjusting for relevant demographic, socioeconomic, and clinical confounders.
The estimated adjusted vaccine effectiveness for the inactivated SARS-CoV-2 vaccine in children aged 6–16 years was 74.5% (95% CI, 73.8–75.2), 91.0% (95% CI, 87.8–93.4), 93.8% (95% CI, 87.8–93.4) for the prevention of COVID-19, hospitalisation, and ICU admission, respectively. For the subgroup of children 6–11 years, the vaccine effectiveness was 75.8% (95% CI, 74.7–76.8) for the prevention of COVID-19 and 77.9% (95% CI, 61.5–87.3) for the prevention of hospitalisation.
Our results suggest that a complete primary immunization schedule with the inactivated SARS-CoV-2 vaccine provides effective protection against severe COVID-19 disease for children 6–16 years.
Agencia Nacional de Investigación y Desarrollo (ANID) Millennium Science Initiative Program and Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias (FONDAP).
Abstract
In light of the ongoing COVID-19 pandemic and the emergence of new SARS-CoV-2 variants, understanding the effectiveness of various booster vaccination regimens is pivotal. In Chile, using a ...prospective national cohort of 3.75 million individuals aged 20 or older, we evaluate the effectiveness against COVID-19-related intensive care unit (ICU) admissions and death of mRNA-based second vaccine boosters for four different three-dose background regimes: BNT162b2 primary series followed by a homologous booster, and CoronaVac primary series followed by an mRNA booster, a homologous booster, and a ChAdOx-1 booster. We estimate the vaccine effectiveness weekly from February 14 to August 15, 2022, by determining hazard ratios of immunization over non-vaccination, accounting for relevant confounders. The overall adjusted effectiveness of a second mRNA booster shot is 88.2% (95%CI, 86.2–89.9) against ICU admissions and 90.5% (95%CI 89.4–91.4) against death. Vaccine effectiveness shows a mild decrease for all regimens and outcomes, probably linked to the introduction of BA.4 and BA.5 Omicron sub-lineages and the waning of immunity. Based on our findings, individuals might not need additional boosters for at least 6 months after receiving a second mRNA booster shot in this setting.
PDF
